JMJ PHARMA
Money flows
no detail for 2025Balance sheet
balance sheet total €850,094 on 31-12-2025in euro
in euro
Position in the sector
13.1%
Higher than 22% of the 13,303 companies filing abbreviated accounts in retail trade (NACE 47) in 2025.
1.26
Higher than 38% of the 13,162 companies filing abbreviated accounts in retail trade (NACE 47) in 2025.
0.2%
Higher than 25% of the 13,223 companies filing abbreviated accounts in retail trade (NACE 47) in 2025.
Net result: middle half · Equity: middle half · Balance sheet total: middle half · Working capital: middle half · Staff: middle half
Staff
€49,334
Staff costs divided by the average number of full-time equivalents.
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2024 | 2023 | 2022 | 20219 months |
|---|---|---|---|---|---|---|
| 76,068 | 90,406 | 88,195 | 42,643 | 77,876 | ||
| 62,351 | 77,115 | 75,151 | 31,181 | 63,274 | ||
| 0 | -0 | 1,665 | 4,261 | 900,036 | ||
| 6,432 | -484 | -22,211 | -50,177 | - | ||
| 49,548 | 62,973 | 61,036 | 61,426 | 110,052 | ||
| - | - | - | -2.3% | 5.1% | ||
| 13.1% | 12.2% | 10.1% | 8.3% | 10.7% | ||
| 1.26 | 1.37 | 1.38 | 1.33 | 1.64 | ||
| 0.43 | 0.42 | 0.36 | 0.47 | 0.74 | ||
| 6.62 | 7.22 | 8.95 | 11.00 | 8.38 | ||
| 1.7% | 12.8% | 9.3% | -40.1% | 17.8% | ||
| 0.2% | 1.6% | 0.9% | -3.3% | 1.9% | ||
| 7.00 | 7.90 | 6.92 | 3.67 | 8.65 | ||
| - | - | - | 20 days | 17 days | ||
| - | - | - | 35 days | 35 days |
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2024 | 2023 | 2022 | 20219 months |
|---|---|---|---|---|---|---|
| Balance sheet: assets | ||||||
20/58 |
850,094 | 901,327 | 951,932 | 1.0m | 1.1m | |
21/28 |
607,997 | 668,448 | 731,535 | 796,652 | 858,360 | |
21 |
256,000 | 304,000 | 352,000 | 400,000 | 448,000 | |
22/27 |
351,647 | 364,099 | 379,186 | 395,802 | 410,010 | |
22 |
350,056 | 361,391 | 372,727 | 384,062 | 395,398 | |
23 |
1,592 | 2,423 | 3,254 | 2,281 | 2,946 | |
24 |
- | 285 | 3,205 | 9,459 | 11,667 | |
28 |
349 | 349 | 349 | 849 | 349 | |
29/58 |
242,097 | 232,879 | 220,397 | 245,357 | 282,414 | |
3 |
159,983 | 162,108 | 163,172 | 159,647 | 155,237 | |
30/36 |
159,983 | 162,108 | 163,172 | 159,647 | 155,237 | |
40/41 |
67,164 | 61,763 | 48,169 | 54,038 | 44,033 | |
40 |
64,659 | 61,763 | 48,169 | 54,038 | 44,033 | |
41 |
2,505 | - | - | - | - | |
54/58 |
14,950 | 8,518 | 9,002 | 31,213 | 81,390 | |
490/1 |
- | 490 | 54 | 459 | 1,755 | |
| Balance sheet: equity and liabilities | ||||||
10/49 |
850,094 | 901,327 | 951,932 | 1.0m | 1.1m | |
10/15 |
111,605 | 109,706 | 95,678 | 86,809 | 121,597 | |
10/11 |
100,000 | 100,000 | 100,000 | 100,000 | 100,000 | |
14 |
11,605 | 9,706 | -4,322 | -13,191 | 21,597 | |
17/49 |
738,488 | 791,621 | 856,254 | 955,200 | 1.0m | |
17 |
545,939 | 621,715 | 696,823 | 771,269 | 845,060 | |
170/4 |
545,939 | 621,715 | 696,823 | 771,269 | 845,060 | |
42/48 |
192,549 | 169,906 | 159,361 | 183,931 | 172,362 | |
42 |
75,775 | 75,108 | 74,446 | 73,791 | 73,142 | |
44 |
86,100 | 76,595 | 66,213 | 80,067 | 72,590 | |
440/4 |
86,100 | 76,595 | 66,213 | 80,067 | 72,590 | |
45 |
30,673 | 18,203 | 18,702 | 30,073 | 26,630 | |
450/3 |
8,911 | 4,960 | 4,899 | 9,724 | 10,787 | |
454/9 |
21,762 | 13,243 | 13,803 | 20,349 | 15,844 | |
47/48 |
0 | - | 0 | 0 | 0 | |
492/3 |
0 | - | 71 | - | 1,755 | |
| Income statement | ||||||
70 |
- | - | - | 999,544 | 710,817 | |
9900 |
167,539 | 174,760 | 209,270 | 182,605 | 142,444 | |
60/61 |
- | - | - | 825,727 | 572,468 | |
62 |
88,801 | 81,618 | 119,508 | 138,572 | 63,816 | |
630 |
60,452 | 63,087 | 66,282 | 65,969 | 41,677 | |
640/8 |
2,670 | 2,736 | 1,568 | 1,390 | 752 | |
9901 |
15,617 | 27,319 | 21,913 | -23,326 | 36,199 | |
75/76B |
207 | 64 | 33 | 142 | 10 | |
75 |
207 | 64 | 33 | 142 | 10 | |
65/66B |
10,859 | 11,437 | 12,745 | 11,605 | 9,003 | |
65 |
10,859 | 11,437 | 12,745 | 11,605 | 9,003 | |
9903 |
4,965 | 15,946 | 9,201 | -34,788 | 27,206 | |
67/77 |
3,065 | 1,918 | 332 | - | 5,609 | |
9904 |
1,900 | 14,028 | 8,869 | -34,788 | 21,597 | |
9905 |
1,900 | 14,028 | 8,869 | -34,788 | 21,597 | |
| Appropriation of the result | ||||||
9906 |
11,605 | 9,706 | -4,322 | -13,191 | 21,597 | |
14P |
9,706 | -4,322 | -13,191 | 21,597 | - | |
| Social balance sheet | ||||||
9087 |
1.8 | 1.7 | 2.4 | 2.8 | 2.7 | |
Hours worked1013 |
2,528 | 2,617 | 3,524 | 4,262 | 2,375 | |
| Document | ||||||
The full notes are in the accounts filed with the NBB.
Source: Annual accounts 2025 at the NBB, filed on 08-06-2026.
Filings
each dot is a set of accounts, on the day it reached the National Bank| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | abbreviated format | 08-06-2026 | 2026-00164774 | |
| 31-12-2024 | full format | 29-07-2025 | 2025-00334178 | |
| 31-12-2023 | micro format | 11-06-2024 | 2024-00138008 | |
| 31-12-2022 | micro format | 02-06-2023 | 2023-00116791 | |
| 31-12-2021 | micro format | 29-06-2022 | 2022-20156744 |
Social balance sheet
| Item | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Employees at the balance-sheet date | 3 | 3 | 3 | 4 | 4 |
| full-time | - | - | 1 | 2 | 2 |
| part-time | 3 | 3 | 2 | 2 | 2 |
| in full-time equivalents | 1.8 | 1.7 | 1.8 | 2.8 | 2.8 |
| 1.8 | 1.7 | 2.4 | 2.8 | 2.5 | |
| On a permanent contract | 3 | 3 | 3 | 4 | 3 |
| Joined | - | 1 | 0 | - | 4 |
| Left | - | 1 | 1 | - | 3 |
Source: social balance sheet in the 2021 to 2025 annual accounts
Investments
fixed assets acquired| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tangible fixed assets | - | - | €1,665 | €3,761 | €419,687 |
| Intangible fixed assets | - | - | - | - | €480,000 |
| Financial fixed assets | - | - | - | €500 | €349 |
| €60,452 | €63,087 | €66,282 | €65,969 | €41,677 |
Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)
Insights on JMJ PHARMA
The operating result for 2025 is 43% lower than in 2024 and the lowest since 2022.
Debt's share of the balance-sheet total falls from 87.8% to 86.9%. Equity is higher and debt is lower.